Acumen Pharmaceuticals, Inc.

09/02/2025

September is World Alzheimer’s Month, a time to raise awareness and challenge stigma of AD worldwide. Each year, organizations, advocates, and communities come together to support people living with dementia and their families through events, education, and action.

We encourage you to explore resources from Alzheimer's Disease International and learn more about how you can get involved, share information, and support the cause.

Together, we can help bring visibility, reduce stigma, and foster understanding for all those affected.

Access the toolkits at: https://www.alzint.org/get-involved/world-alzheimers-month/

08/15/2025

At , our CMO Eric Siemers MD shared our exciting progress in Alzheimer’s drug development with NeurologyLive!

Dr. Siemers gave an overview on how pTau217 blood-based biomarker could reduce PET scans and cut screening costs by ~40%, a major step toward more efficient clinical trials. He also discussed how our investigational antibody, sabirnetug, shows 8750-fold selectivity for toxic amyloid beta oligomers.

Watch Dr. Siemers break down the data and how our approach could be poised to reshape the treatment of early Alzheimer’s disease: https://tinyurl.com/83zz4mbe

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

08/12/2025

Today we announced our second quarter financial results and business highlights.

🔗Click link to read the release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-reports-second-quarter-2025-financial

08/11/2025

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

August's 'Ask Acumen' featured team member is Alexander Colin, CPA, Accounting Manager.

🔗 Click the link below to get a behind-the-scenes look at Alex's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

08/07/2025

Today, our Head of HR Julie Bockenstette presented at the LEAP HR: Life Sciences East Conference in Boston, sharing her journey in building strong, strategic business partnerships.

Julie spoke about the evolving role of HR as a key driver of business outcomes and how aligning people strategy with company goals can help life sciences organizations grow with clarity and impact.

Thank you LEAP HR for the opportunity to learn, connect and contribute to the conversation.

08/01/2025

All good things must come to an end, and while the Acumen team is sad to leave , it’s been a wonderful week of sharing knowledge and innovation in the ’s field. We’ll see you all next year!

07/30/2025

It’s day 4 of and it has been a great conference so far, filled with insightful conversations and great connections -- we would love to talk to you at booth #1441 if you want to stop by!

07/29/2025

Today Erika Cline, PhD is presenting a poster on a nonclinical study evaluating the relative selectivity of sabirnetug targeting AβOs versus Aβ monomers at .

You can view the poster in person at AAIC or on our website.

Link: https://acumenpharm.com/publications/

07/29/2025

Thank you to everyone who attended our reception last night in beautiful Toronto at ! The Acumen team has been grateful to connect with so many of our ALTITUDE-AD study sites and partners, it’s been wonderful to spend time in person with so many people dedicated to Alzheimer’s research and innovation.

07/28/2025

Today Prajakta Dinesh Mangeshkar, MSc, MS is presenting a poster titled “ALTITUDE-AD: Cost savings using a pTau217 screening assay in an ongoing Phase 2 study of sabirnetug in early Alzheimer's disease” at .

You can view the poster in person at AAIC or on our website.

Link: https://acumenpharm.com/publications/

07/28/2025

We’re pleased to share our latest findings from our Phase 2 ALTITUDE-AD study and a nonclinical study of sabirnetug at the Alzheimer's Association International Conference 2025!

➡️Visit our posters to learn more about:

🔹The use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug, which reduced total screening costs by ~40% across U.S. and Canadian sites

🔹A nonclinical study evaluating the relative selectivity of sabirnetug for amyloid beta oligomers (AβO), which showed sabirnetug achieved the highest binding affinities to AβO preparations among the monoclonal antibodies tested with minimal interaction with monomeric Aβ

🔗Don’t miss our posters at AAIC and read our press release for more details: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-showing-utility-ptau217

07/27/2025

Toronto, we’ve arrived! The Acumen team is officially ready for the kickoff tomorrow. We look forward to engaging with everyone during an exciting week focused on , stop by booth #1441 to meet the team!